JP2013523748A5 - - Google Patents

Download PDF

Info

Publication number
JP2013523748A5
JP2013523748A5 JP2013502716A JP2013502716A JP2013523748A5 JP 2013523748 A5 JP2013523748 A5 JP 2013523748A5 JP 2013502716 A JP2013502716 A JP 2013502716A JP 2013502716 A JP2013502716 A JP 2013502716A JP 2013523748 A5 JP2013523748 A5 JP 2013523748A5
Authority
JP
Japan
Prior art keywords
group
alkyl
formulation
solvent system
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013502716A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013523748A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/030271 external-priority patent/WO2011123416A1/en
Publication of JP2013523748A publication Critical patent/JP2013523748A/ja
Publication of JP2013523748A5 publication Critical patent/JP2013523748A5/ja
Pending legal-status Critical Current

Links

JP2013502716A 2010-03-29 2011-03-29 注射用薬物送達製剤 Pending JP2013523748A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31871710P 2010-03-29 2010-03-29
US61/318,717 2010-03-29
PCT/US2011/030271 WO2011123416A1 (en) 2010-03-29 2011-03-29 Injectable drug delivery formulation

Publications (2)

Publication Number Publication Date
JP2013523748A JP2013523748A (ja) 2013-06-17
JP2013523748A5 true JP2013523748A5 (enExample) 2014-05-15

Family

ID=44246149

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013502716A Pending JP2013523748A (ja) 2010-03-29 2011-03-29 注射用薬物送達製剤

Country Status (5)

Country Link
US (1) US8697105B2 (enExample)
EP (1) EP2552969A1 (enExample)
JP (1) JP2013523748A (enExample)
CA (1) CA2794958A1 (enExample)
WO (1) WO2011123416A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697105B2 (en) 2010-03-29 2014-04-15 Surmodics, Inc. Injectable drug delivery formulation
CN109200013A (zh) * 2011-12-05 2019-01-15 因赛普特有限责任公司 医用有机凝胶方法和组合物
WO2016100861A1 (en) * 2014-12-19 2016-06-23 Baxter International, Inc. Flowable hemostatic composition
AU2020340441A1 (en) * 2019-08-29 2022-03-24 Paul Douglas Godfrin Hydrogels as oral delivery dosage forms, methods of making and using same
CN112569179B (zh) * 2020-12-25 2022-12-27 上海交通大学医学院附属第九人民医院 一种可注射水凝胶体系及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
DK89592D0 (da) * 1992-07-07 1992-07-07 Helle Broendsted Laegemiddelafgivelsesindretning samt fremgangsmaade til fremstilling deraf
US6884842B2 (en) * 1997-10-14 2005-04-26 Alnis Biosciences, Inc. Molecular compounds having complementary surfaces to targets
IL155866A0 (en) * 2003-05-12 2003-12-23 Yissum Res Dev Co Responsive polymeric system
US20070065483A1 (en) 2005-09-21 2007-03-22 Chudzik Stephen J In vivo formed matrices including natural biodegradable polysaccharides and uses thereof
JP2009529967A (ja) 2006-03-15 2009-08-27 サーモディクス，インコーポレイティド 天然生分解性ポリサッカライドの疎水性誘導体及びそれらの使用
US7638344B2 (en) 2006-06-28 2009-12-29 Surmodics, Inc. Active agent eluting matrices with particulates
JP5694664B2 (ja) 2006-09-29 2015-04-01 サーモディクス，インコーポレイティド 生分解性眼用インプラント及び眼の病気を治療する方法
US20080220047A1 (en) * 2007-03-05 2008-09-11 Sawhney Amarpreet S Low-swelling biocompatible hydrogels
US20090022805A1 (en) 2007-06-28 2009-01-22 Joram Slager Polypeptide microparticles having sustained release characteristics, methods and uses
EP2185637B1 (en) * 2007-09-19 2013-04-03 SurModics, Inc. Biocompatible foams, systems, and methods
US8790701B2 (en) 2008-04-28 2014-07-29 Surmodics, Inc. Poly-α(1→4)glucopyranose-based matrices with hydrazide crosslinking
CA2741415A1 (en) 2008-10-22 2010-04-29 Surmodics, Inc. Swellable biodegradable polymeric matrices and methods
CA2763522A1 (en) 2009-06-02 2010-12-09 Surmodics, Inc. Silane-functionalized hydrophobic .alpha.(1.fwdarw.-4)glucopyranose polymers and polymeric matrices for implantation or injection
US20100302403A1 (en) 2009-06-02 2010-12-02 Raytheon Company Generating Images With Different Fields Of View
US8697105B2 (en) 2010-03-29 2014-04-15 Surmodics, Inc. Injectable drug delivery formulation

Similar Documents

Publication Publication Date Title
Jiang et al. Progress on ocular siRNA gene‐silencing therapy and drug delivery systems
JP6700348B2 (ja) 持続型薬物送達インプラント
AU2015257651B2 (en) Compounds for treating ophthalmic diseases and disorders
RU2664686C2 (ru) Способ лечения повышенного внутриглазного давления с помощью внутриглазной системы доставки лекарственного средства с замедленным высвобождением
US20240285518A1 (en) Ocular hydrogel tyrosine kinase inhibitor implants
US20100098772A1 (en) Drug delivery systems and methods for treating neovascularization
US20110117189A1 (en) Ophthalmic compositions for treating pathologies of the posterior segment of the eye
US20170273901A1 (en) Sunitinib formulations and methods for use thereof in treatment of ocular disorders
JP2007535552A5 (enExample)
RU2690841C1 (ru) Способы лечения патологических состояний глаза с помощью имплантата с долговременной доставкой лекарственного вещества
JP2013501579A5 (enExample)
JP2013523748A5 (enExample)
KR102266014B1 (ko) 안질환 예방 또는 치료용 점안 조성물
US8697105B2 (en) Injectable drug delivery formulation
EP4433076A1 (en) Compositions and methods for the treatment of ocular diseases and injuries
Shin et al. Biodegradable intrascleral implant of triamcinolone acetonide in experimental uveitis
US20190275001A1 (en) Sunitinib formulations and methods for use thereof in treatment of ocular disorders
HK40092417A (zh) 用於治疗眼科疾病和障碍的化合物